DomoSafety, a digital health leader offering a private cloud platform for patient monitoring and decision support for home care, has launched a pilot project with Roche Pharma (Switzerland) Ltd. The project aims at improving the quality of life of people living with Spinal Muscular Atrophy, a rare neuromuscular disease.
Spinal muscular atrophy (SMA) is a severe, inherited, progressive neuromuscular disease that causes devastating muscle atrophy and disease-related complications. It is the most common genetic cause of infant mortality and one of the most common rare diseases, affecting approximately one in 11,000 babies. SMA leads to the progressive loss of nerve cells in the spinal cord that controls muscle movement. Depending on the type of SMA, an individual’s physical strength and their ability to walk, eat or breathe can be significantly diminished or lost.